72 related articles for article (PubMed ID: 21037024)
1. Braking bad: blockade of inhibitory pathways improves interleukin-15 therapy.
Carson WE
Clin Cancer Res; 2010 Dec; 16(24):5917-9. PubMed ID: 21037024
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
5. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
6. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
7. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
Wing K; Yamaguchi T; Sakaguchi S
Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
[TBL] [Abstract][Full Text] [Related]
8. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
9. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
Chambers CA; Kuhns MS; Egen JG; Allison JP
Annu Rev Immunol; 2001; 19():565-94. PubMed ID: 11244047
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4: new insights into its biological function and use in tumor immunotherapy.
Egen JG; Kuhns MS; Allison JP
Nat Immunol; 2002 Jul; 3(7):611-8. PubMed ID: 12087419
[TBL] [Abstract][Full Text] [Related]
12. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
13. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
14. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.
Perrin PJ; Maldonado JH; Davis TA; June CH; Racke MK
J Immunol; 1996 Aug; 157(4):1333-6. PubMed ID: 8759711
[TBL] [Abstract][Full Text] [Related]
16. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
Mokyr MB; Kalinichenko T; Gorelik L; Bluestone JA
Cancer Res; 1998 Dec; 58(23):5301-4. PubMed ID: 9850053
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 blockade: autoimmunity as treatment.
Kapadia D; Fong L
J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
[No Abstract] [Full Text] [Related]
18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CTLA-4 promotes airway inflammation in naive mice exposed to aerosolized allergen but fails to prevent inhalation tolerance.
Alenmyr L; Matheu V; Uller L; Greiff L; Malm-Erjefält M; Ljunggren HG; Persson CG; Korsgren M
Scand J Immunol; 2005 Nov; 62(5):437-44. PubMed ID: 16305640
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.
Raziorrouh B; Ulsenheimer A; Schraut W; Heeg M; Kurktschiev P; Zachoval R; Jung MC; Thimme R; Neumann-Haefelin C; Horster S; Wächtler M; Spannagl M; Haas J; Diepolder HM; Grüner NH
Gastroenterology; 2011 Oct; 141(4):1422-31, 1431.e1-6. PubMed ID: 21763239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
